学历背景 1986.09-1990.07 四川大学，本科 1990.09-1993.07 中国科学院上海有机化学研究所，理学硕士 1993.09-1996.07 中国科学院上海有机化学研究所，理学博士 国外学习研究经历 1997.07-2000.09 美国国立卫生研究院国家癌症研究所(NIH, NCI)，博士后 2006.10-2007.02 美国密西根大学(University of Michigan)医学院，访问教授 2008.11-2009.05 德国波恩大学(University of Bonn)，生命和医学科学研究所(The Life & Medical Sciences Institute)，访问教授 工作经历 1996.07-1997.07 中科院上海有机化学研究所，助理研究员，项目组长 2000.09-2000.12中科院上海有机化学研究所，研究员（百人计划引进），课题组长； 2001.01-2017.02中科院上海药物研究所，研究员，课题组长，博士生导师； 2017.03-至今 苏州大学苏州医学院药学院，特聘教授，博士生导师，苏州医学院副院长

1、靶向非酶结合位点（蛋白-蛋白相互作用、变构位点和非活性构像）及多靶点干预的小分子和多肽先导化合物的发现和结构优化及其作用机理研究 2、基于蛋白翻译后修饰调控（聚焦磷酸化/去磷酸化、泛素化/去泛素化信号通路）的分子靶向诊疗试剂的发现研究 3、生物正交反应方法学及其在时空可控蛋白修饰调控上的应用研究 4、生物活性复杂天然产物的高效全合成及其药物化学生物学研究

Sun, Y.; Tang, W.; Wang, M.; Ni, H.-X.; Long, Y.-Q.*Synthesis of piperazic acid-containing cyclodepsipeptide core of verucopeptin. Chin. J. Chem.2023, in Press. (cover paper) Chen, C.; Guo, S.-M.; Sun, Y.; Li, H.; Hu, N.; Yao, K.; Ni, H.; Xia, Z.; Xu, B.; Xie, X.*; Long, Y.-Q.*Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into β-position to the carboxylic acid. Eur.J. Med. Chem.2023, 251, 115267. Sun, Y.; Tang, W.; Ni, H.-X.; Wang, M.; Huang, B.; Long, Y.-Q.*Convergent synthesis of tetrahydropyranyl side chain of verucopeptin, an antitumor antibiotic active against multidrug-resistant cancers. Chem. Commun.2022, 58, 13447-13450. (back cover paper) Zhou, Z.; Feng, S.; Zhou, J.; Ji, X.* and Long, Y.-Q.* On-Demand activation of a bioorthogonal prodrug of SN-38 with fast reaction kinetics and high releasing efficiency in vivo. J. Med. Chem.2022, 65, 333-342. Song, L.-R.; Li, H.; Wang, S.-F.; Lin, J.-P.; Huang, B.*; Long, Y.-Q.* Metal-free hypervalent iodine-promoted tandem carbonyl migration and unactivated C(Ph)-C(Alkyl) bond cleavage for quinolone scaffold synthesis. Chem. Commun.2022, 58, 8340-8343. (cover paper) Rashad, A. A.; Song, L.-R.; Holmes, A. P.; Acharya, K.; Zhang, S.; Wang, Z.-L.; Gary, E.; Xie, X.; Pirrone, V.; Kutzler, M. A.; Long, Y.-Q.* and Chaiken, I.* Bifunctional chimera that coordinately targets human immunodeficiency virus 1 envelope gp120 and the host-cell CCR5 coreceptor at the virus–cell interface. J. Med. Chem.2018, 61, 5020-5033. Li, H.; Huang, Q.; Chen, C.; Xu, B.; Wang, H.-Y.*; Long, Y.-Q.* Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold. J. Med. Chem.2017, 60, 2697-2717. Liu, G.; Xue, D.; Yang, J.; Wang, J.; Liu, X.; Huang, W.; Li, J.; Long, Y.-Q.*; Tan, W.;* and Zhang, A.* Design, synthesis, and pharmacological Evaluation of 2‑(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)‑N‑aryl Propanamides as Novel Smoothened (Smo) Antagonists. J. Med. Chem.2016, 59, 11050-11068. Hu, W.; Lin, J.-P.; Zhang, F.-H.; Song, L.-R.; Long, Y.-Q.*Direct Synthesis of 2-Aryl-4-quinolones via Transition Metal-free Intramolecular Oxidative C(sp3)-H/C(sp3)-H Coupling. Org. Lett.2015,17, 1268-1271. Yang, C.; Xu, Z.; Zhao, Z.; Li, L.; Zhao, T.; Peng, D.; Xu, M.; Rong, R.*; Long, Y.*; Zhu, T.* A Novel Proteolysis-resistant Cyclic Helix B Peptide Ameliorates Kidney Ischemia Reperfusion Injury. BBA - Molecular Basis of Disease. 2014, 1842, 2306-2317. Lin, J.-P.; Zhang, F.-H.; Long, Y.-Q.* Solvent/oxidant-switchable synthesis of multisubstituted quinazolines and benzimidazoles via metal-free selective oxidative annulation of arylamidines. Org. Lett.2014, 16, 2822-2825. Long, Y.-Q.*; Huang, S.-X.; Zawahir, Z.; Xu, Z.-L.; Li, H.-Y.; Sanchez, T.; Zhi, Y.; De Houwer, S.; Christ, F.; Debyser, Z.; Neamati, N.* Design of Cell-Permeable Stapled-Peptides as HIV-1 Integrase Inhibitors. J. Med. Chem.2013, 56, 5601-5612. Lin, J.-P.; Long, Y.-Q.* Transition Metal-Free One-Pot Synthesis of 2-Substituted 3-Carboxy-4-Quinolone and Chromone Derivatives. Chem. Commun.2013, 49, 5313-5315. Zeng, L.-F.; Wang, Y.; Kazemi, R.; Xu, S.; Xu, Z.-L.; Sanchez, T. W.; Yang, L.-M.; Debnath, B.; Odde, S.; Xie, H.; Zheng, Y.-T.; Ding, J.; Neamati, N. and Long, Y.-Q.* Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. J. Med. Chem.2012, 55, 9492-9509. Huang, S.-X.; Li, H.-Y.; Liu, J.-Y.; Morisseau, C.; Hammock, B. D. Long, Y.-Q.* Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties. J. Med. Chem.2010, 53, 8376-8386. Liu, S., Zeng, L.-F., Wu, L., Yu, X., Xue, T., Gunawan, A., Long, Y.-Q.,* and Zhang, Z.-Y.* Targeting Inactive Enzyme Conformation: Aryl Diketoacid Derivatives as a New Class of PTP1B Inhibitors. J. Am. Chem. Soc.2008, 130, 17075-17084. Long, Y.-Q.*; Xue, T.; Song, Y.-L.; Liu, Z.-L.; Huang, S.-X.; Yu, Q. Synthesis and utilization of chiral a-methylated a-amino acids with a carboxyalkyl side chain in the design of novel Grb2-SH2 peptide inhibitors free of phosphotyrosine. J. Med. Chem.2008, 51, 6371-6380. Li, H.-Y.; Zawahir, Z.; Song, L.-D.; Long, Y.-Q.* and Neamati, N.* Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. J. Med. Chem.2006, 49, 4477-4486. Song, Y.-L.; Peach, M.; Roller, P. P.; Qiu, S.; Wang, S. and Long, Y.-Q.* Discovery of a novel non-phosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives. J. Med. Chem.2006, 49, 1585-1596. Long, Y.-Q.*; Jiang, X.-H.; Dayam, R.; Sanchez, T.; Shoemaker, R.; Sei, S.; Neamati, N.* Rational design and synthesis of novel dimeric diketoacid containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase. J. Med. Chem.2004, 47, 2561-2573.